#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Brain stem glioma Anti-HLA antibody test positive Cerebellar ataxia Squamous cell carcinoma of the oral cavity Basal cell naevus syndrome Malignant central nervous system neoplasm Epidermolysis bullosa Neuroendocrine carcinoma Soft tissue necrosis Pemphigoid Gastrointestinal disorder Glioma Endocrine ophthalmopathy Myocarditis Angelman's syndrome More trials…

    Learn about Rare Diseases

    Proteus syndrome – Life with Disease Hereditary motor and sensory neuropathy Rhabdomyosarcoma – Diagnostics Pulmonary sarcoidosis – Basic Information Hereditary angioedema – Life with Disease Stevens-Johnson syndrome Erdheim-Chester disease – Basic Information Undifferentiated sarcoma – Treatment Metachromatic leukodystrophy – Treatment Rhabdoid tumour More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Infliximab Concizumab Etravirine Bepranemab [89Zr]Bms-986279 Vutrisiran ALENDRONATE SODIUM TRIHYDRATE Niraparib Tioguanine Vilobelimab Oxacillin Crd-4730 Psilocybine Metoprolol Mirvetuximab Soravtansine Mva-Hbvac Antithrombin Iii Human Abc-35B-116 Cloxacillin Tildacerfont More therapies…

    Learn about Your Condition

    Anal fistula Hypopituitarism Dent's disease Rheumatic disorder Adrenal insufficiency Osteonecrosis of jaw Brain stem glioma Postprandial hypoglycaemia Lyme disease Colitis Pustular psoriasis Lung disorder Asthma Mitral valve prolapse Pyoderma gangrenosum More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Diagnostic Consultative Centre Ascendent OOD

Diagnostic Consultative Centre Ascendent OOD

Ulitsa Bacho Kiro 47, Sofia, 1202, Bulgaria

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland

  • Testing GIA632 compared to placebo in adults with moderate to severe atopic dermatitis to measure effectiveness and safety

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Bulgaria Czechia France Germany Poland

  • Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

    Not yet recruiting

    3 1
    Investigated Drugs:
    • HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN
    Belgium Bulgaria Estonia Finland Germany Poland +2

  • Bioavailability of 50 mg dimenhydrinate granules taken with or without water versus reference formulations for nausea and vomiting in healthy volunteers

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • DIMENHYDRINATE
    Bulgaria

  • A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

    Not recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Comparative Bioavailability of Inhaled Levodopa (Levodopa Cyclops) versus Inhaled Levodopa Powder with Carbidopa in Healthy Adults for Parkinson’s Disease

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Parkinson’s disease
    Investigated Drugs:
    • Carbidopa
    • Levodopa
    Bulgaria
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!